Literature DB >> 19300882

What we have learned from the Xaliproden Sanofi-aventis trials.

P Douillet1, J M Orgogozo.   

Abstract

Mesh:

Substances:

Year:  2009        PMID: 19300882     DOI: 10.1007/s12603-009-0045-6

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


× No keyword cloud information.
  6 in total

1.  Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease.

Authors:  M W Weiner
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

2.  IAGG workshop: health promotion program on prevention of late onset dementia.

Authors:  S Andrieu; I Aboderin; J P Baeyens; J Beard; A Benetos; G Berrut; M Brainin; H B Cha; L K Chen; P Du; B Forette; F Forette; A Franco; L Fratiglioni; S Gillette-Guyonnet; G Gold; F Gomez; R Guimaraes; D Gustafson; A Khachaturian; J Luchsinger; F Mangialasche; H Mathiex-Fortunet; J P Michel; E Richard; L S Schneider; A Solomon; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

3.  Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.

Authors:  Nicola Coley; Adeline Gallini; Sandrine Andrieu
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

Review 4.  Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.

Authors:  L S Schneider; F Mangialasche; N Andreasen; H Feldman; E Giacobini; R Jones; V Mantua; P Mecocci; L Pani; B Winblad; M Kivipelto
Journal:  J Intern Med       Date:  2014-03       Impact factor: 8.989

5.  Use of biomarkers in Alzheimer's trials.

Authors:  B Vellas
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 6.  Current treatment and recent clinical research in Alzheimer's disease.

Authors:  Judith Neugroschl; Mary Sano
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.